These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1280 related items for PubMed ID: 19364426

  • 1. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH, Eldridge B, Bishop D, Alexander A, Lesperance M, Blood P, Lim J, Ludgate C.
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W.
    Int J Radiat Oncol Biol Phys; 2009 Mar 15; 73(4):1009-16. PubMed ID: 18963539
    [Abstract] [Full Text] [Related]

  • 5. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR, Presti JC, Gill H, Brooks J, Hancock SL.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):341-7. PubMed ID: 15145146
    [Abstract] [Full Text] [Related]

  • 6. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ.
    J Urol; 2003 Nov 01; 170(5):1860-3. PubMed ID: 14532793
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK.
    Urology; 2004 Jul 01; 64(1):84-9. PubMed ID: 15245941
    [Abstract] [Full Text] [Related]

  • 8. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA.
    Cancer; 2002 Dec 01; 95(11):2302-7. PubMed ID: 12436435
    [Abstract] [Full Text] [Related]

  • 9. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.
    King CR, Spiotto MT.
    Int J Radiat Oncol Biol Phys; 2008 May 01; 71(1):23-7. PubMed ID: 18207668
    [Abstract] [Full Text] [Related]

  • 10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 11. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy.
    Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW.
    J Urol; 2003 Nov 01; 170(5):1833-7. PubMed ID: 14532786
    [Abstract] [Full Text] [Related]

  • 12. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS, Mydin A, Jones SO, Christie J, Lim JT, Truong PT, Ludgate CM.
    Int J Radiat Oncol Biol Phys; 2011 Dec 01; 81(5):e713-9. PubMed ID: 21277102
    [Abstract] [Full Text] [Related]

  • 13. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 14. Salvage radiotherapy for biochemical recurrence after radical prostatectomy.
    Terai A, Matsui Y, Yoshimura K, Arai Y, Dodo Y.
    BJU Int; 2005 Nov 15; 96(7):1009-13. PubMed ID: 16225518
    [Abstract] [Full Text] [Related]

  • 15. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR, Presti JC, Brooks JD, Gill H, Spiotto MT.
    Int J Radiat Oncol Biol Phys; 2008 Apr 01; 70(5):1472-7. PubMed ID: 17935902
    [Abstract] [Full Text] [Related]

  • 16. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
    Neuhof D, Hentschel T, Bischof M, Sroka-Perez G, Hohenfellner M, Debus J.
    Int J Radiat Oncol Biol Phys; 2007 Apr 01; 67(5):1411-7. PubMed ID: 17275204
    [Abstract] [Full Text] [Related]

  • 17. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
    Sasaki T, Nakamura K, Shioyama Y, Ohga S, Toba T, Urashima Y, Yoshitake T, Terashima H, Koga H, Naito S, Noma H, Komatsu K, Yamaguchi A, Hiratsuka Y, Hirano T, Hanada K, Abe M, Fujisawa Y, Honda H.
    Anticancer Res; 2006 Apr 01; 26(3B):2367-74. PubMed ID: 16821618
    [Abstract] [Full Text] [Related]

  • 18. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
    Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Laverdiere J, Larue H, Lacombe L, Fradet Y.
    Prostate; 2004 Feb 15; 58(3):269-76. PubMed ID: 14743466
    [Abstract] [Full Text] [Related]

  • 19. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors.
    Brooks JP, Albert PS, Wilder RB, Gant DA, McLeod DG, Poggi MM.
    J Urol; 2005 Dec 15; 174(6):2204-8, discussion 2208. PubMed ID: 16280764
    [Abstract] [Full Text] [Related]

  • 20. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.
    J Clin Oncol; 2009 Jun 20; 27(18):2924-30. PubMed ID: 19433689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.